VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES
The effectiveness of traditional chemotherapy (with temozolomide, fotemustine, lomustine) alone or in combination with whole brain radiotherapy in melanoma patients with cerebral metastases does not exceed 7–10 % with no significant impact on survival, which is around 2–4 months. Targeted therapy...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-04-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/248 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849403933185802240 |
|---|---|
| author | D. R. Naskhletashvili V. A. Gorbunova A. Kh. Bekyashev L. V. Demidov G. Yu. Kharkevich S. M. Banov I. V. Samoylenko K. А. Baryshnikov K. V. Orlova I. А. Utyashev N. N. Petenko I. G. Markina E. A. Moskvina S. V. Medvedev |
| author_facet | D. R. Naskhletashvili V. A. Gorbunova A. Kh. Bekyashev L. V. Demidov G. Yu. Kharkevich S. M. Banov I. V. Samoylenko K. А. Baryshnikov K. V. Orlova I. А. Utyashev N. N. Petenko I. G. Markina E. A. Moskvina S. V. Medvedev |
| author_sort | D. R. Naskhletashvili |
| collection | DOAJ |
| description | The effectiveness of traditional chemotherapy (with temozolomide, fotemustine, lomustine) alone or in combination with whole brain radiotherapy in melanoma patients with cerebral metastases does not exceed 7–10 % with no significant impact on survival, which is around 2–4 months. Targeted therapy helped to improve survival of patients with disseminated melanoma and BRAF V600 mutations. The use of targeted drugs in patients with brain metastases allows to control the tumor process and to succeed in treatment of cerebral metastases. According to currently available research data and our own results, the effectiveness of targeted therapy with vemurafenib in melanoma patients positive for BRAF V600 mutations with brain metastases reaches 18.0–44.5 % with median survival of 5.3–8.0 months. Evidences suggest that the use of vemurafenib in melanoma patients with brain metastases ensure effective disease control in most of the cases and has a significant advantage comparing to conventional chemotherapy and whole brain radiotherapy. According to the results of these studies vemurafenib can be recommended as a 1st line targeted drug for treatment of melanoma patients with BRAF V600 mutations and brain metastases. Despite the existence of blood-brain barrier and efflux systems, new targeted drugs showed promising results in treatment of brain metastases. Over the last few years we have enhanced our understanding of brain metastasis mechanisms, principles of blood-brain barrier functioning, and ways of cancer drugs penetration into the central nervous system. Targeted therapy is constantly developing and will play an increasing role in treatment of melanoma cerebral metastases in the future with finding of new targets. |
| format | Article |
| id | doaj-art-b2ac3cf2f6194ffca9ad2854e4269286 |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2017-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-b2ac3cf2f6194ffca9ad2854e42692862025-08-20T03:37:08ZrusABV-pressОпухоли головы и шеи2222-14682411-46342017-04-0164303410.17650/2222-1468-2016-6-4-30-34233VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASESD. R. Naskhletashvili0V. A. Gorbunova1A. Kh. Bekyashev2L. V. Demidov3G. Yu. Kharkevich4S. M. Banov5I. V. Samoylenko6K. А. Baryshnikov7K. V. Orlova8I. А. Utyashev9N. N. Petenko10I. G. Markina11E. A. Moskvina12S. V. Medvedev13N.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Burdenko Neurosurgery Research InstituteN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterN.N. Blokhin Russian Cancer Research CenterThe effectiveness of traditional chemotherapy (with temozolomide, fotemustine, lomustine) alone or in combination with whole brain radiotherapy in melanoma patients with cerebral metastases does not exceed 7–10 % with no significant impact on survival, which is around 2–4 months. Targeted therapy helped to improve survival of patients with disseminated melanoma and BRAF V600 mutations. The use of targeted drugs in patients with brain metastases allows to control the tumor process and to succeed in treatment of cerebral metastases. According to currently available research data and our own results, the effectiveness of targeted therapy with vemurafenib in melanoma patients positive for BRAF V600 mutations with brain metastases reaches 18.0–44.5 % with median survival of 5.3–8.0 months. Evidences suggest that the use of vemurafenib in melanoma patients with brain metastases ensure effective disease control in most of the cases and has a significant advantage comparing to conventional chemotherapy and whole brain radiotherapy. According to the results of these studies vemurafenib can be recommended as a 1st line targeted drug for treatment of melanoma patients with BRAF V600 mutations and brain metastases. Despite the existence of blood-brain barrier and efflux systems, new targeted drugs showed promising results in treatment of brain metastases. Over the last few years we have enhanced our understanding of brain metastasis mechanisms, principles of blood-brain barrier functioning, and ways of cancer drugs penetration into the central nervous system. Targeted therapy is constantly developing and will play an increasing role in treatment of melanoma cerebral metastases in the future with finding of new targets.https://ogsh.abvpress.ru/jour/article/view/248vemurafenibmelanomabrain metastasestargeted therapy |
| spellingShingle | D. R. Naskhletashvili V. A. Gorbunova A. Kh. Bekyashev L. V. Demidov G. Yu. Kharkevich S. M. Banov I. V. Samoylenko K. А. Baryshnikov K. V. Orlova I. А. Utyashev N. N. Petenko I. G. Markina E. A. Moskvina S. V. Medvedev VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES Опухоли головы и шеи vemurafenib melanoma brain metastases targeted therapy |
| title | VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES |
| title_full | VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES |
| title_fullStr | VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES |
| title_full_unstemmed | VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES |
| title_short | VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES |
| title_sort | vemurafenib in treatment of melanoma with brain metastases |
| topic | vemurafenib melanoma brain metastases targeted therapy |
| url | https://ogsh.abvpress.ru/jour/article/view/248 |
| work_keys_str_mv | AT drnaskhletashvili vemurafenibintreatmentofmelanomawithbrainmetastases AT vagorbunova vemurafenibintreatmentofmelanomawithbrainmetastases AT akhbekyashev vemurafenibintreatmentofmelanomawithbrainmetastases AT lvdemidov vemurafenibintreatmentofmelanomawithbrainmetastases AT gyukharkevich vemurafenibintreatmentofmelanomawithbrainmetastases AT smbanov vemurafenibintreatmentofmelanomawithbrainmetastases AT ivsamoylenko vemurafenibintreatmentofmelanomawithbrainmetastases AT kabaryshnikov vemurafenibintreatmentofmelanomawithbrainmetastases AT kvorlova vemurafenibintreatmentofmelanomawithbrainmetastases AT iautyashev vemurafenibintreatmentofmelanomawithbrainmetastases AT nnpetenko vemurafenibintreatmentofmelanomawithbrainmetastases AT igmarkina vemurafenibintreatmentofmelanomawithbrainmetastases AT eamoskvina vemurafenibintreatmentofmelanomawithbrainmetastases AT svmedvedev vemurafenibintreatmentofmelanomawithbrainmetastases |